Clinical outcomes of new algorithm for diagnosis and treatment of Tuberculosis sepsis in HIV patients

Background: Despite effort to diagnose tuberculosis (TB) in the Human Immunodeficiency Virus (HIV) infected population, 45% of adults with HIV that had a previously unknown reason for death, demonstrated TB was the cause by autopsy examination. We aimed to assess the clinical outcomes of implementation a new algorithm for diagnosis and treatment of tuberculosis (TB) related sepsis among PLHIV presenting with life-threatening illness. Methods: This study is a prospective cohort conducted in three-referral hospitals in Kilimanjaro, recruited 97 PLHIV from February through June 2018. Patients provided urine and sputum samples for testing lateral flow – lipoarabinomannan (LF-LAM) and Xpert Mycobacterium tuberculosis (MTB)/rifampicin (RIF) assays, respectively. Anti-TB was prescribed to patients with positive LF-LAM or Xpert MTB/RIF or received broad-spectrum antibiotics but deteriorated. Results: Of 97 patients, 84 (87%) provided urine and sputa, and 13 (13%) provided only urine. The mean age (95% confidence interval) was 40 (38–43) years and 52 (54%) were female. In 84 patients, LF-LAM increased TB detection from 26 (31%) by Xpert MTB/RIF to 41 (55%) by both tests. Of 97 patients, 69 (71%) prescribed anti-TB, 67% (46/69) and 33% (23/69) had definitive and probable TB respectively. Sixteen (16.5%) patients died, of which one died before treatment, 73% (11/15) died within 7 days of admission. The 30-day survival was similar in both treatment groups (log rank = 0.1574). Mortality was significantly higher among hospitalized patients compared to outpatients (P ≤ 0.027). Conclusion: Implementation of new algorithm increased TB case detection in patients that could have been missed by Xpert MTB/RIF assay. Survival of PLHIV with confirmed or probable TB was comparable to those of PLHIV that were treated with broad-spectrum antibiotics alone. Further work should focus on the optimal timing and content of the immediate antimicrobial regimen for sepsis among PLHIV in TB-endemic settings.

[1]  A. Odeyemi,et al.  Survival model analysis of tuberculosis treatment among patients with human immunodeficiency virus coinfection , 2019, International journal of mycobacteriology.

[2]  W. Deressa,et al.  Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study , 2019, BMC Infectious Diseases.

[3]  M. B. Shiferaw,et al.  Delay in tuberculosis diagnosis and treatment in Amhara state, Ethiopia , 2019, BMC Health Services Research.

[4]  S. Heysell,et al.  Therapeutic Drug Monitoring: The Need for Practical Guidance. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Mutambayi,et al.  Associated factors with unsuccessful tuberculosis treatment outcomes among tuberculosis/HIV coinfected patients with drug-resistant tuberculosis , 2018, International journal of mycobacteriology.

[6]  N. Ford,et al.  Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis. , 2018, The lancet. HIV.

[7]  K. Mortimer,et al.  The Early Recognition and Management of Sepsis in Sub-Saharan African Adults: A Systematic Review and Meta-Analysis , 2018, International journal of environmental research and public health.

[8]  A. Sahebkar,et al.  Bacterial Co-infections in HIV/AIDS-positive Subjects: A Systematic Review and Meta-analysis , 2018, Folia medica.

[9]  M. Mendelson,et al.  Incremental yield and cost of urine Determine TB-LAM and sputum induction in seriously ill adults with HIV , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[10]  B. Ledergerber,et al.  Delayed Sputum Culture Conversion in Tuberculosis–Human Immunodeficiency Virus–Coinfected Patients With Low Isoniazid and Rifampicin Concentrations , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  D. Boulware,et al.  Etiology of Sepsis in Uganda Using a Quantitative Polymerase Chain Reaction-based TaqMan Array Card , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  S. Hashemian,et al.  Linezolid: a review of its properties, function, and use in critical care , 2018, Drug design, development and therapy.

[13]  T. Chiller,et al.  The important role of co-infections in patients with AIDS and progressive disseminated histoplasmosis (PDH): A cohort from Colombia , 2018, Medical mycology case reports.

[14]  M. Matee,et al.  Improved performance of Xpert MTB/RIF assay on sputum sediment samples obtained from presumptive pulmonary tuberculosis cases at Kibong’oto infectious diseases hospital in Tanzania , 2017, BMC Infectious Diseases.

[15]  S. Mancinelli,et al.  Tuberculosis Case Finding With Combined Rapid Point-of-Care Assays (Xpert MTB/RIF and Determine TB LAM) in HIV-Positive Individuals Starting Antiretroviral Therapy in Mozambique , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  G. Bernard,et al.  Effect of an Early Resuscitation Protocol on In-hospital Mortality Among Adults With Sepsis and Hypotension: A Randomized Clinical Trial , 2017, JAMA.

[17]  S. Lawn,et al.  Disseminated tuberculosis among hospitalised HIV patients in South Africa: a common condition that can be rapidly diagnosed using urine-based assays , 2017, Scientific Reports.

[18]  Alimuddin Zumla,et al.  The cursed duet today: Tuberculosis and HIV-coinfection. , 2017, Presse medicale.

[19]  S. Lawn,et al.  Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis , 2015, AIDS.

[20]  D. Cirillo,et al.  Challenges and perspectives in the diagnosis of extrapulmonary tuberculosis , 2014, Expert review of anti-infective therapy.

[21]  E. Shankar,et al.  HIV-Mycobacterium tuberculosis co-infection: a 'danger-couple model' of disease pathogenesis. , 2014, Pathogens and disease.

[22]  M. Uplekar,et al.  Systematic screening for active tuberculosis: rationale, definitions and key considerations. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[24]  Irene Ayakaka,et al.  Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology , 2009, Journal of Clinical Microbiology.

[25]  Paul Nunn,et al.  Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes , 2007, The Lancet.